Researchers at the University of Texas at Austin have developed a noninvasive, wearable ultrasound patch that helps users reach REM sleep faster and maintain it longer. The NEUSLeeP device, which simultaneously monitors brain activity, shows promise as a potential therapeutic tool for managing chronic insomnia, depression, and PTSD.
Race, age, and other factors are linked to disparities in care for people with narcolepsy.
ABM was acquired by Cadence Health Capital last month. A new leadership team at the neurology-forward sleep company plans to streamline operations and expand the clinical reach of validated technologies for sleep apnea, insomnia, and neurodegenerative disease.
What can sleep physicians do when obstructive sleep apnea patients can't afford every recommended therapy?
Nexalin Technology has secured a US patent for its Deep Intracranial Frequency Stimulation (DIFS) platform, protecting its noninvasive, in-home treatment method for insomnia, anxiety, and depression through 2042. The patent reinforces the company’s strategy to expand physician-supervised, drug-free neurostimulation care via its virtual clinic model.
The medical technology company is transitioning leadership to focus on its next phase of growth and commercial traction for its obstructive sleep apnea therapy in the US market.
A post hoc analysis of the SELECT trial suggests that semaglutide 2.4 mg is associated with a significantly lower incidence of obstructive sleep apnea in adults with overweight or obesity and established cardiovascular disease. While these findings are promising, Novo Nordisk notes that semaglutide is not currently approved to treat obstructive sleep apnea and further research is required.
A retrospective study explores how surgical and pharmacologic weight-loss strategies stack up in cost, effectiveness, and health outcomes.
A mastery-based cognitive-behavioral model centers on "nightmare efficacy" to help clinicians create personalized treatment plans for youth.